Researchers have developed a new opioid drug, UMB 425, which is as strong as morphine, but has reduced tolerance over time and no obvious toxic effects. The drug acts on two different opioid receptors in the body. The team plans to continue testing with the goal of developing two compounds derived form UMB 425 that would lead to Phase I clinical trials. Read more and access the study abstract.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
